It should be noted, however, that HDAC6 inhibitors can also be used for the treatment of systemic lupus erythematosus, a B cell-associated immune system disease, by correcting abnormal cell metabolism and reducing the inflammatory environment (Choi et al., 2018; Ren et al., 2019). This evidence concerns the gene HDAC6 and systemic lupus erythematosus.